Updated on 18 December 2014
Follitrope's biological, immunological, and physicochemical properties are identical with natural FSH and is found to be highly stable compared to previous urinary derived FSH products
Singapore: LG Lifesciences has signed an exclusive pact with China's Weijian pharma group obtaining exclusive rights to sell ovulation induction medication-Follitrope in China. Follitrope is a treatment to increase follicle stimulating hormone (FSH) developed using the company's own recombinant DNA methods.
Follitrope's biological, immunological, and physicochemical properties are identical with natural FSH and is found to be highly stable compared to previous urinary derived FSH products. Mr Jung II-jae, CEO, LG Lifesciences, said, "The contract provided a chance to promote infertility treatments in China. Also, the company is making its best effort, together with our partner company, to provide new opportunities and value to our customers in the Chinese female infertility market through this product."
LG Lifesciences has been active in Asia Pacific region since a couple of years. Recently the company had signed an agreement with Japan-based Mochida Pharmaceutical to co-develop and commercialize a biosimilar for the autoimmune disease treatment drug Humira.
Under the terms of the agreement, Mochida will have exclusive rights for the development and sales of the Humira biosimilar in Japan, which is currently in clinical studies by LG Life Sciences. After commercialization, LG Life Sciences will produce and supply finished products to Mochida.